Private company

Finch Therapeutics Group, Inc.

In its 2024 annual report the company says: “We are a microbiome technology company with a portfolio of intellectual property and microbiome assets. Our objectives are to realize the value of our intellectual property estate through licensing our technology to collaboration partners and enforcing our patent rights against infringing parties through intellectual property litigation and, in certain cases, to generate additional data on selected product candidates through academic collaborations.”4 It is headquartered in Boston, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address75 State Street, Suite 100, Boston, Ma 021092
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are a microbiome technology company with a portfolio of intellectual property and microbiome assets. Our objectives are to realize the value of our intellectual property estate through licensing our technology to collaboration partners and enforcing our patent rights against infringing parties through intellectual property litigation and, in certain cases, to generate additional data on selected product candidates through academic collaborations. We have a robust intellectual property estate reflecting our pioneering role in the microbiome therapeutics field, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Our assets include CP101, an investigational, orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection, or…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-78374.8%Operating margin5
-69863.6%Net margin5
-87.6%Revenue growth, 20235
-326.6%Return on equity5
0.00×Debt to equity5
-$31.5MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development68¢$7.2M
  • Income tax32¢$3.5M

Out of $107.0K in revenue.5 The company lost money this year.

Financial statements

Revenue675$107.0K in 2023−99% since 2020
0$5.0M$10.0M$15.0M$20.0M2020: $7.7M$7.7M20202021: $18.5M$18.5M2021+140%2022: $861.0K$861.0K2022−95%2023: $107.0K$107.0K2023−88%
Operating income675-$83.9M in 2023+113% since 2020
-$150.0M-$100.0M-$50.0M02020: -$39.4M-$39.4M20202021: -$60.0M-$60.0M2021+52%2022: -$115.6M-$115.6M2022+93%2023: -$83.9M-$83.9M2023−27%
Net income675-$74.8M in 2023+90% since 2020
-$150.0M-$100.0M-$50.0M02020: -$39.3M-$39.3M20202021: -$58.2M-$58.2M2021+48%2022: -$114.6M-$114.6M2022+97%2023: -$74.8M-$74.8M2023−35%
Fiscal year20192020202120222023
Revenue$7.7M6$18.5M7$861.0K5$107.0K5
Research and development$33.1M6$57.3M7$52.9M5$7.2M5
Operating expenses$78.5M7$116.5M5$84.0M5
Operating income-$39.4M6-$60.0M7-$115.6M5-$83.9M5
Income before tax-$58.2M7-$114.6M5-$78.2M5
Income tax$06$07$05-$3.5M5
Net income-$39.3M6-$58.2M7-$114.6M5-$74.8M5
Earnings per share-$1.487-$72.125-$46.595
Earnings per share (diluted)-$1.487-$72.125-$46.595
Shares (weighted, basic)39.2M shares71.6M shares51.6M shares5
Shares (weighted, diluted)39.2M shares71.6M shares51.6M shares5

Compare Finch Therapeutics Group, Inc. with another company

Corporate structure

Finch Therapeutics Group, Inc. sits at the top of its group. 4 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Finch Therapeutics Group, Inc.

  • Chidozie Ugwumba Filed SC 13G on Finch Therapeutics Group, Inc., latest Dec 13, 2023 (2 filings since Feb 14, 2022)
  • Thomas Layton Walton Filed SC 13G on Finch Therapeutics Group, Inc., latest Feb 14, 2022
  • Finch Therapeutics Group, Inc. Boston, Massachusetts
    • Finch Research and Development, LLC Subsidiary · Delaware, United States
    • Finch Therapeutics Holdings, LLC Subsidiary · Delaware, United States
    • Finch Therapeutics, Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Finch Therapeutics Group, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$869.0K5 Dec 31, 2023$25.2M5 Dec 31, 2022−96.6%
Accumulated depreciation$275.0K5 Dec 31, 2023$9.3M5 Dec 31, 2022−97.0%
Property and equipment, net$594.0K5 Dec 31, 2023$15.9M5 Dec 31, 2022−96.3%
Finance-lease assets$1.0K7 Dec 31, 2022$22.0K7 Dec 31, 2021−95.5%
Operating-lease assets (leased space)$26.6M5 Dec 31, 2023$32.8M5 Dec 31, 2022−18.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$25.1M5 Dec 31, 2023$71.0M5 Dec 31, 2022−64.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$07 Dec 31, 2022$18.1M7 Dec 31, 2021−100.0%

Leadership

Who has led Finch Therapeutics Group, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mark Burnham Smith2021
  2. Matthew P. Blischak2023

Chief financial officer

  1. Gregory D. Perry2021–2022
  2. Lance E. Thibault2023

Chief operating officer

  1. Marc Blaustein2021–2023
2025
Board members and other officers (11)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Finch Research and Development, LLC Delaware3
  • Finch Therapeutics Holdings, LLC Delaware3
  • Finch Therapeutics, Inc. Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Oct 21, 20248-K Listing notice or transfer; Regulation FD disclosure25
  2. Aug 12, 20248-K Other events26
  3. May 24, 20248-K Listing notice or transfer27
  4. May 17, 20248-K Listing notice or transfer28
  5. Apr 3, 20248-K Listing notice or transfer29
  6. Feb 23, 20248-K Listing notice or transfer; Other events30
  7. Nov 17, 20238-K Listing notice or transfer31
  8. Jul 7, 20238-K Ended a material agreement32
  9. Jun 28, 20238-K Other events33
  10. Jun 23, 20238-K Executive or director change34
  11. Jun 9, 20238-K Bylaws or fiscal year changed; Shareholder vote35
  12. May 30, 20238-K Executive or director change36
  13. May 16, 2023New chief executive Matthew P. Blischak becomes CEO10
  14. Mar 18, 2021New chief executive Mark Burnham Smith becomes CEO11

Calendar

When it reported results

  1. May 10, 2023Reported quarterly or annual results37
  2. Mar 23, 2023Reported quarterly or annual results38
  3. Nov 10, 2022Reported quarterly or annual results39
  4. Aug 11, 2022Reported quarterly or annual results40
  5. May 16, 2022Reported quarterly or annual results41
  6. Mar 31, 2022Reported quarterly or annual results42
  7. Jan 10, 2022Reported quarterly or annual results43
  8. Nov 10, 2021Reported quarterly or annual results44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

110 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 37 major events, 34 insider forms, 3 large holders, 22 other. The latest 20:

  1. Nov 12, 202415-12G EDGAR
  2. Nov 4, 2024EFFECT EDGAR
  3. Nov 1, 2024POS AM EDGAR
  4. Nov 1, 2024S-8 POS EDGAR
  5. Nov 1, 2024S-8 POS EDGAR
  6. Nov 1, 2024S-8 POS EDGAR
  7. Oct 31, 202425 EDGAR
  8. Oct 21, 20248-K EDGAR
  9. Aug 13, 202410-Q EDGAR
  10. Aug 12, 20248-K EDGAR
  11. Jun 10, 20244 EDGAR
  12. May 24, 20248-K EDGAR
  13. May 24, 20244 EDGAR
  14. May 17, 20248-K EDGAR
  15. May 10, 202410-Q EDGAR
  16. Apr 26, 202410-K/A EDGAR
  17. Apr 3, 20248-K EDGAR
  18. Mar 29, 20244 EDGAR
  19. Mar 28, 2024144 EDGAR
  20. Mar 25, 202410-K EDGAR

The 110 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 2 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 28, 2024SMISEK JEFFERY ADirectorSale8,242$2.58$21.2KForm 4
Nov 22, 2023SMISEK JEFFERY ADirectorSale1,470$3.64$5.4KForm 4
Jun 9, 2023Graf Susan EDirectorBuy5,010$0.27$1.4KForm 4
Feb 21, 2023Blaustein MarcChief Operating OfficerSale4,619$0.38$1.8KForm 4
Oct 21, 2022Blaustein MarcChief Operating OfficerSale3,636$1.39$5.1KForm 4
Oct 21, 2022Vittiglio JosephChief Business & Legal OfficerSale3,636$1.39$5.1KForm 4
Dec 20, 2021Haft NicholasDirectorBuy63,850$10.18$650.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Chidozie UgwumbaSC 13G, 2 filings Feb 14, 2022 to Dec 13, 202345
  • Thomas Layton WaltonSC 13G, 1 filing Feb 14, 202246

SEC filer profile

How Finch Therapeutics Group, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARFinch Therapeutics Group, Inc.1
  • CIK0001733257
  • Employer ID (EIN)82-34335581
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address75 State Street, Suite 100, Boston, MA 021091
  • Phone617-229-64991
  • Shares outstanding1,605,763 as of Aug 9, 20249
  • Public float$9.1M as of Jun 30, 202347
  • On EDGAR sinceMar 5, 20181
  • Filings173 in all: 8-K (45), 4 (41), 3 (15), 10-Q (11), CORRESP (6), SC 13G (4), UPLOAD (4), 10-K (3)1
    All 36 form types

    D (3), DEFA14A (3), EFFECT (3), S-8 (3), S-8 POS (3), 144 (2), D/A (2), DEF 14A (2), S-1/A (2), SC 13D (2), SEC STAFF LETTER (2), 10-K/A (1), 10-Q/A (1), 15-12G (1), 25 (1), 4/A (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), PRE 14A (1), S-1 (1), S-1MEF (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 25, 2024
    Quarterly report (10-Q) Aug 13, 2024
    Proxy statement (DEF 14A) Apr 26, 2023
    Latest 8-K (8-K) Oct 21, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47